Loading
A phase 3 trial of Rinatabart sesutecan, Bevacizumab, Carboplatin in ovarian cancer, run by Genmab, now recruiting.
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer is a phase 3 interventional study registered as NCT07564141 by Genmab, with 688 participants planned, started 2026-08-28 and due to reach its primary completion in 2029-12. Interventions recorded: Rina-S, Bevacizumab, Carboplatin, Gemcitabine, Paclitaxel. Conditions listed: Platinum-Sensitive Ovarian Cancer, Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rinatabart sesutecan, Genmab, Platinum-sensitive ovarian cancer, Bevacizumab.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Paclitaxel / nab-paclitaxel.
Shares Rinatabart sesutecan, Genmab, Paclitaxel / nab-paclitaxel, Gemcitabine.
Shares Rinatabart sesutecan, Genmab, Paclitaxel / nab-paclitaxel, Gemcitabine.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Paclitaxel / nab-paclitaxel.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Paclitaxel / nab-paclitaxel, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/